Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy

(2011) Katsuhiro Masago et al.   Clinical Lung Cancer

Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma

(2010) Babita Saigal et al.   ANTI-CANCER DRUGS

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines

(2010) Hua Cheng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer

(2010) Mark A. Socinski et al.   Journal of Thoracic Oncology

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study

(2010) Martin Reck et al.   LUNG CANCER

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS

(2010) Furugaki   ONCOLOGY REPORTS

Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer

(2009) T. Donnem et al.   ANNALS OF ONCOLOGY

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

(2009) Francisco Robert et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Frequency of and variables associated with the EGFR mutation and its subtypes

(2009) Tomoaki Tanaka et al.   INTERNATIONAL JOURNAL OF CANCER

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

(2009) A F Gazdar   ONCOGENE

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

(2008) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors

(2007) Aristidis Polyzos   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY